Edesa Biotech (EDSA) Receivables - Net (2013 - 2026)
Edesa Biotech (EDSA) posted Receivables - Net of $431325.0 for Q4 2025, down 32.91% sequentially from $642866.0 in Q3 2025, and up 23.01% YoY from $350639.0 in Q4 2024.
Edesa Biotech (EDSA) Receivables - Net (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Receivables - Net for 13 years, with the latest figure at $431325.0 in Q4 2025.
- Quarterly Receivables - Net rose 23.01% year-over-year to $431325.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $431325.0 (up 23.01% YoY) and the FY2025 annual result came in at $642866.0, up 137.3% from the prior year.
- Receivables - Net eased to $431325.0 in Q4 2025 per EDSA's latest filing, from $642866.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $7.8 million in Q1 2021 and troughed at $42866.0 in Q2 2023.
- A 5-year average of $1.4 million and a median of $634704.5 in 2023 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2021 and 2023: Receivables - Net jumped 9187.72% in 2021, then plunged 96.95% in 2023.
- Over 5 years, Receivables - Net stood at $2.9 million in 2021, then tumbled by 95.64% to $125477.0 in 2022, then surged by 492.59% to $743569.0 in 2023, then plunged by 52.84% to $350639.0 in 2024, then grew by 23.01% to $431325.0 in 2025.
- According to Business Quant data, Receivables - Net over the past three periods registered $431325.0, $642866.0, and $286743.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228,051.00 |
| Jun 30, 2026 | 228,051.00 |
| Dec 31, 2025 | 431,325.00 |
| Dec 31, 2025 | 431,325.00 |
| Sep 30, 2025 | 642,866.00 |
| Sep 30, 2025 | 642,866.00 |
| Jun 30, 2025 | 286,743.00 |
| Jun 30, 2025 | 286,743.00 |
| Mar 31, 2025 | 382,440.00 |
| Mar 31, 2025 | 382,440.00 |
| Dec 31, 2024 | 350,639.00 |
| Dec 31, 2024 | 350,639.00 |
| Sep 30, 2024 | 270,908.00 |
| Sep 30, 2024 | 270,908.00 |
| Jun 30, 2024 | 551,064.00 |
| Jun 30, 2024 | 551,064.00 |
| Mar 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 743,569.00 |
| Dec 31, 2023 | 743,569.00 |